Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
 

This article is part of the supplement: 23rd European Workshop for Rheumatology Research

Meeting abstract

High-affinity antibodies against β2-glycoprotein I

S Cucnik, T Kveder, A Ambrozic and B Borut

Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia

from 23rd European Workshop for Rheumatology Research
Marseille, France. 27 February – 2 March 2003

Arthritis Res Ther 2003, 5(Suppl 1):7doi:10.1186/ar637

Published: 24 February 2003

Background

Antibodies against β2-glycoprotein I (anti-β2GPI) are believed to be of low affinity and thus unable to bind to the free antigen in a solution.

Objective

The aim of our study was to determine the affinity of IgG anti-β2GPI, isolated by affinity chromatography.

Methods

A β2GPI affinity column was prepared by CNBr-activated agarose without spacer arms and human purified unnicked β2GPI. The IgG fraction from the protein G column was applied to the column and bound antibodies were eluted with various solutions: A) 0.1 M glycine / 0.5 M NaCl / 0.1% Tween 20 pH 2.5; B) 0.1 M glycine / 4 M NaCl / 0.1% Tween 20 pH 2.5; C) 0.1 M sodium borate pH 10 and D) 25% ethylene glycol. Eluted fractions containing anti-β2GPI antibodies were neutralised and analysed by ELISA using various binding buffers. The level of anti-β2GPI antibodies in each sample was derived from the standard curve according to the defined dilutions of monoclonal antibodies (AUG are arbitrary units of IgG monoclonals).

Results

Increased concentrations of sodium ions in the binding solution from 0.15, 0.25, 0.50, 1.11, 2.07 and 4.0 M NaCl did not completely prevent the binding between isolated antibodies and β2-GPI (79.8, 65.3, 36.1, 19.9, 12.0 and 8.1 AUG, respectively).

Conclusion

In contrast to the common opinion that all anti-β2GPI autoantibodies are of low affinity, we clearly showed that at least one subset among them was of high affinity.

Have something to say? Post a comment on this article!


© 1999-2008 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.